1 citations
,
March 2022 in “JAAD case reports” This case report describes a rare occurrence of injection site reactions in a 77-year-old woman with eosinophilic fasciitis using subcutaneous methotrexate, marking the first documented instance in this patient population.
105 citations
,
September 1995 in “Journal of The American Academy of Dermatology” This review discusses the use of recombinant cytokines as therapeutic agents in clinical settings and describes the range of cutaneous complications associated with their use, including both minor and severe skin reactions.
2 citations
,
March 2022 in “PubMed” In this study, 19.6% of COVID-19 vaccine recipients reported post-vaccination mucocutaneous effects, mostly mild and self-limiting; the reactions were similarly frequent for Covishield and Covaxin.
1 citations
,
June 2020 in “Annals of the rheumatic diseases” In this study, 93% of patients with inflammatory arthritis remained on the adalimumab biosimilar ABP 501 for 24 weeks after switching from the originator, with some switching back due to adverse reactions or reduced effectiveness.
July 2024 in “Journal of Investigative Dermatology” In these two clinical trials, DS-2325a, a KLK5 inhibitor, was found to be generally safe and well tolerated in healthy volunteers, with mild and non-serious adverse events, suggesting its potential for further development as a treatment for Netherton Syndrome.